ArticleLeukemia2007
Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
Article in Leukemia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- The Fusion Genes and Their Relation with Genetic Variants in Egyptian AML Patients.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML.Blood cancer journal · 2024Article
- The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression.Biomedicines · 2024Review
- The whole is greater than the sum of its parts: Long-read sequencing for solving clinical problems in haematology.Journal of cellular and molecular medicine · 2024Article
- Stable thyroid cancer in a patient with thoracic aortic aneurysm and MYH11 variation.Endocrinology, diabetes & metabolism case reports · 2024Article
- Association between Immunophenotypic Parameters and Molecular Alterations in Acute Myeloid Leukemia.Biomedicines · 2023Review
- Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges.Frontiers in oncology · 2022Review
- Incidental identification of inv(16)(p13.1q22)/Cold Spring Harbor molecular case studies · 2021Article
- Rare type I CBFβ/MYH11 fusion transcript in primary acute myeloid leukemia with inv(16)(p13.1q22): a case report.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia.The Journal of clinical investigation · 2020Article
- De Novo Acute Myeloid Leukemia with CombinedCase reports in hematology · 2020Article
- Therapy-related myeloid neoplasms - what have we learned so far?World journal of stem cells · 2016Review
- Article
- Characteristics of hematologic malignancies with coexisting t(9;22) and inv(16) chromosomal abnormalities.Blood research · 2014Article
- A focused review of hematopoietic neoplasms occurring in the therapy-related setting.International journal of clinical and experimental pathology · 2014Review
- Article
- Childhood acute myeloid leukemia with bone marrow eosinophilia caused by t(16;21)(q24;q22).International journal of hematology · 2012Article
- Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.British journal of pharmacology · 2011Review
- Article
- Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.Current opinion in oncology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spectrum of CBFB-MYH11 fusion transcripts in acute myeloid leukemia (AML) M4eo with inv(16)/t(16;16) is heterogeneous. Approximately 85% show type A CBFB-MYH11 fusion transcripts. In addition, more than 10 different fusion transcripts have been reported. The prognostic impact and biological background of rare fusion transcripts remain open. In this study, a molecular characterization of CBFB-MYH11 transcripts in 162 patients with CBFB-MYH11 positive AML at diagnosis was performed. In total, 128 patients (79.0%) showed the fusion transcript type A, whereas nine different rare CBFB-MYH11 fusion genes were detected in 34 cases (21.0%). Rare fusion transcripts were found more frequently in therapy-related AML (P=0.0106). Numerical gains of the chromosomes 8, 21 and 22 were more frequently associated with type A (28.3%) than with rare fusions (12.9%) (P=0.012). Median white blood cell (WBC) count was higher in type A (35.4 G/l; range=1.1-279 G/l) than in cases with rare types (7.8 G/l; range=0.8-148.0 G/l) (P<0.0001). Rare fusion transcripts were correlated with an atypical cytomorphology not primarily suggestive for the FAB subtype M4eo (P=0.0203). Immunophenotype revealed lower CD2, CD13, CD33 and CD90 levels than in type A fusion cases (P=0.036, 0.002, 0.029 and 0.045, respectively). However, the type of fusion was not an independent prognostic parameter.
Indexed as
Identifiers
17287858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.